tubercidin + bortezomib + lenalidomide + filgrastim

A combination regimen composed of four agents: **tubercidin** (an adenosine analog with experimental antineoplastic activity through inhibition of nucleic acid synthesis), **bortezomib** (a selective 26S proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma that induces apoptosis by disrupting proteasome-mediated protein degradation[2][4][10][14]), **lenalidomide** (an immunomodulatory drug and derivative of thalidomide, approved for multiple myeloma and myelodysplastic syndromes, modulating immune responses and promoting cancer cell death, particularly through Ikaros degradation and CD38 upregulation in combination therapies[1]), and **filgrastim** (a recombinant human granulocyte colony-stimulating factor, G-CSF, used to stimulate neutrophil production and treat chemotherapy-induced neutropenia).\nThis four-drug combination has no established, unique brand or regimen name and is not a standard protocol, but each agent has clear roles: tubercidin as an investigational antitumor agent, bortezomib and lenalidomide for synergistic anti-myeloma activity[1][2], and filgrastim for neutropenia prophylaxis or treatment.